Bose Tanima
Institute of Human Genetics, University of Regensburg, Franz-Josef-Strauss-Allee 11, D-93053 Regensburg, Germany.
Brain Sci. 2017 Nov 7;7(11):148. doi: 10.3390/brainsci7110148.
Pharmacological targeting of memory cells is an attractive treatment strategy in various autoimmune diseases, such as psoriasis and rheumatoid arthritis. Multiple sclerosis is the most common inflammatory disorder of the central nervous system, characterized by focal immune cell infiltration, activation of microglia and astrocytes, along with progressive damage to myelin sheaths, axons, and neurons. The current review begins with the identification of memory cell types in the previous literature and a recent description of the modulation of these cell types in T, B, and resident memory cells in the presence of different clinically approved multiple sclerosis drugs. Overall, this review paper tries to determine the potential of memory cells to act as a target for the current or newly-developed drugs.
在各种自身免疫性疾病,如银屑病和类风湿性关节炎中,对记忆细胞进行药理学靶向治疗是一种有吸引力的治疗策略。多发性硬化症是中枢神经系统最常见的炎症性疾病,其特征是局部免疫细胞浸润、小胶质细胞和星形胶质细胞活化,以及髓鞘、轴突和神经元的进行性损伤。本综述首先在以往文献中识别记忆细胞类型,并描述了在不同临床批准的多发性硬化症药物存在的情况下,这些细胞类型在T细胞、B细胞和驻留记忆细胞中的调节情况。总体而言,本综述试图确定记忆细胞作为当前或新开发药物靶点的潜力。